Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
The Motley Fool
by newsfeedback@fool.com (Adé Hennis)February 16, 2026
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/16/2026